Fucoxanthin and lipid metabolism: A minireview
Abstract Aims Accumulating data suggest that food supplementation with seaweeds which traditionally are an important part of food culture in South-East Asian countries might lead to essential health benefits. In this short review, we summarize findings from experimental studies on the effects of fuc...
Gespeichert in:
Veröffentlicht in: | Nutrition, metabolism, and cardiovascular diseases metabolism, and cardiovascular diseases, 2015-10, Vol.25 (10), p.891-897 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 897 |
---|---|
container_issue | 10 |
container_start_page | 891 |
container_title | Nutrition, metabolism, and cardiovascular diseases |
container_volume | 25 |
creator | Muradian, Kh Vaiserman, A Min, K.-J Fraifeld, V.E |
description | Abstract Aims Accumulating data suggest that food supplementation with seaweeds which traditionally are an important part of food culture in South-East Asian countries might lead to essential health benefits. In this short review, we summarize findings from experimental studies on the effects of fucoxanthin (a carotenoid derived from brown seaweeds) on lipid metabolism, adiposity, and related conditions and discuss the possible underlying mechanisms. Data synthesis Supplementation of fucoxanthin or its derivatives consistently attenuated body and visceral fat weight gain, lipid accumulation in the liver, decreases insulin resistance, and improves the plasma lipid profile in rodents fed a high-fat diet. It should however be noted that in diabetic/obese KK-Ay mice with genetically compromised insulin signaling, fucoxanthin might increase the plasma levels of cholesterol and low-density lipoproteins. The anti-obesity effects of fucoxanthin are apparently mediated by the hormones leptin and adiponectin through their common target AMK-activated protein kinase, resulting in downregulation of lipogenic enzymes and upregulation of lipolytic enzymes. Fucoxanthin also suppresses adipocyte differentiation and induces the expression of uncoupling proteins in visceral adipose tissue. Conclusions The results of experimental studies suggest that consumption of fucoxanthin and its derivatives as nutritional supplements is a promising option for prevention and treatment of obesity and a wide variety of related pathologies, including metabolic syndrome, type 2 diabetes, and heart disease. Yet, clinical trials are warranted to assess a therapeutic value of fucoxanthin. |
doi_str_mv | 10.1016/j.numecd.2015.05.010 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1716935057</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0939475315001404</els_id><sourcerecordid>1716935057</sourcerecordid><originalsourceid>FETCH-LOGICAL-c553t-1fecebd12b4f5c2583017c342ce6a768c5ed79ca26bd88cc83c427523a3f4ad43</originalsourceid><addsrcrecordid>eNqFkUtv1EAQhEcIRJbAP0DIRy423fPw2ByQoigBpEgcSM6jcU9bzOLH4rGB_PvMagMHLkgl9aWqWv21EK8RKgSs3-2raRuZQiUBTQVZCE_EDk0LpbKyfSp20Kq21NaoM_EipT2AsqD0c3Ema9TYarUT1fVG828_rd_iVPgpFEM8xFCMvPpuHmIa3xcXxRinuPDPyL9eime9HxK_epzn4u766vbyU3nz5ePny4ubkoxRa4k9E3cBZad7Q9I0CtCS0pK49rZuyHCwLXlZd6FpiBpFWlojlVe99kGrc_H21HtY5h8bp9WNMREPg5943pJDi3WrDBibrfpkpWVOaeHeHZY4-uXeIbgjKbd3J1LuSMpBFkKOvXncsHUjh7-hP2iy4cPJwPnOfPviEkWeiENmQasLc_zfhn8LaMggyQ_f-Z7Tft6WKTN06JJ04L4ev3V8FhoA1KDVA43wj4w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1716935057</pqid></control><display><type>article</type><title>Fucoxanthin and lipid metabolism: A minireview</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Muradian, Kh ; Vaiserman, A ; Min, K.-J ; Fraifeld, V.E</creator><creatorcontrib>Muradian, Kh ; Vaiserman, A ; Min, K.-J ; Fraifeld, V.E</creatorcontrib><description>Abstract Aims Accumulating data suggest that food supplementation with seaweeds which traditionally are an important part of food culture in South-East Asian countries might lead to essential health benefits. In this short review, we summarize findings from experimental studies on the effects of fucoxanthin (a carotenoid derived from brown seaweeds) on lipid metabolism, adiposity, and related conditions and discuss the possible underlying mechanisms. Data synthesis Supplementation of fucoxanthin or its derivatives consistently attenuated body and visceral fat weight gain, lipid accumulation in the liver, decreases insulin resistance, and improves the plasma lipid profile in rodents fed a high-fat diet. It should however be noted that in diabetic/obese KK-Ay mice with genetically compromised insulin signaling, fucoxanthin might increase the plasma levels of cholesterol and low-density lipoproteins. The anti-obesity effects of fucoxanthin are apparently mediated by the hormones leptin and adiponectin through their common target AMK-activated protein kinase, resulting in downregulation of lipogenic enzymes and upregulation of lipolytic enzymes. Fucoxanthin also suppresses adipocyte differentiation and induces the expression of uncoupling proteins in visceral adipose tissue. Conclusions The results of experimental studies suggest that consumption of fucoxanthin and its derivatives as nutritional supplements is a promising option for prevention and treatment of obesity and a wide variety of related pathologies, including metabolic syndrome, type 2 diabetes, and heart disease. Yet, clinical trials are warranted to assess a therapeutic value of fucoxanthin.</description><identifier>ISSN: 0939-4753</identifier><identifier>EISSN: 1590-3729</identifier><identifier>DOI: 10.1016/j.numecd.2015.05.010</identifier><identifier>PMID: 26141943</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Adipocyte differentiation ; Adipocytes - cytology ; Adiponectin ; Animals ; Anti-Obesity Agents ; Brown seaweeds ; Cardiovascular ; Cell Differentiation - drug effects ; Diet, High-Fat ; Fucoxanthin ; Humans ; Ion Channels ; Leptin ; Lipid Metabolism - drug effects ; Lipids - blood ; Lipogenesis - drug effects ; Lipolysis - drug effects ; Liver - drug effects ; Liver - metabolism ; Lypogenesis and lipolysis ; Mice ; Mitochondrial Proteins ; Obesity ; Rats ; Rodents ; Uncoupling Protein 1 ; Uncoupling proteins ; Weight Gain - drug effects ; Xanthophylls - administration & dosage ; Xanthophylls - therapeutic use ; Xanthophylls - toxicity</subject><ispartof>Nutrition, metabolism, and cardiovascular diseases, 2015-10, Vol.25 (10), p.891-897</ispartof><rights>Elsevier B.V.</rights><rights>2015 Elsevier B.V.</rights><rights>Copyright © 2015 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c553t-1fecebd12b4f5c2583017c342ce6a768c5ed79ca26bd88cc83c427523a3f4ad43</citedby><cites>FETCH-LOGICAL-c553t-1fecebd12b4f5c2583017c342ce6a768c5ed79ca26bd88cc83c427523a3f4ad43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.numecd.2015.05.010$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,781,785,3551,27929,27930,46000</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26141943$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Muradian, Kh</creatorcontrib><creatorcontrib>Vaiserman, A</creatorcontrib><creatorcontrib>Min, K.-J</creatorcontrib><creatorcontrib>Fraifeld, V.E</creatorcontrib><title>Fucoxanthin and lipid metabolism: A minireview</title><title>Nutrition, metabolism, and cardiovascular diseases</title><addtitle>Nutr Metab Cardiovasc Dis</addtitle><description>Abstract Aims Accumulating data suggest that food supplementation with seaweeds which traditionally are an important part of food culture in South-East Asian countries might lead to essential health benefits. In this short review, we summarize findings from experimental studies on the effects of fucoxanthin (a carotenoid derived from brown seaweeds) on lipid metabolism, adiposity, and related conditions and discuss the possible underlying mechanisms. Data synthesis Supplementation of fucoxanthin or its derivatives consistently attenuated body and visceral fat weight gain, lipid accumulation in the liver, decreases insulin resistance, and improves the plasma lipid profile in rodents fed a high-fat diet. It should however be noted that in diabetic/obese KK-Ay mice with genetically compromised insulin signaling, fucoxanthin might increase the plasma levels of cholesterol and low-density lipoproteins. The anti-obesity effects of fucoxanthin are apparently mediated by the hormones leptin and adiponectin through their common target AMK-activated protein kinase, resulting in downregulation of lipogenic enzymes and upregulation of lipolytic enzymes. Fucoxanthin also suppresses adipocyte differentiation and induces the expression of uncoupling proteins in visceral adipose tissue. Conclusions The results of experimental studies suggest that consumption of fucoxanthin and its derivatives as nutritional supplements is a promising option for prevention and treatment of obesity and a wide variety of related pathologies, including metabolic syndrome, type 2 diabetes, and heart disease. Yet, clinical trials are warranted to assess a therapeutic value of fucoxanthin.</description><subject>Adipocyte differentiation</subject><subject>Adipocytes - cytology</subject><subject>Adiponectin</subject><subject>Animals</subject><subject>Anti-Obesity Agents</subject><subject>Brown seaweeds</subject><subject>Cardiovascular</subject><subject>Cell Differentiation - drug effects</subject><subject>Diet, High-Fat</subject><subject>Fucoxanthin</subject><subject>Humans</subject><subject>Ion Channels</subject><subject>Leptin</subject><subject>Lipid Metabolism - drug effects</subject><subject>Lipids - blood</subject><subject>Lipogenesis - drug effects</subject><subject>Lipolysis - drug effects</subject><subject>Liver - drug effects</subject><subject>Liver - metabolism</subject><subject>Lypogenesis and lipolysis</subject><subject>Mice</subject><subject>Mitochondrial Proteins</subject><subject>Obesity</subject><subject>Rats</subject><subject>Rodents</subject><subject>Uncoupling Protein 1</subject><subject>Uncoupling proteins</subject><subject>Weight Gain - drug effects</subject><subject>Xanthophylls - administration & dosage</subject><subject>Xanthophylls - therapeutic use</subject><subject>Xanthophylls - toxicity</subject><issn>0939-4753</issn><issn>1590-3729</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUtv1EAQhEcIRJbAP0DIRy423fPw2ByQoigBpEgcSM6jcU9bzOLH4rGB_PvMagMHLkgl9aWqWv21EK8RKgSs3-2raRuZQiUBTQVZCE_EDk0LpbKyfSp20Kq21NaoM_EipT2AsqD0c3Ema9TYarUT1fVG828_rd_iVPgpFEM8xFCMvPpuHmIa3xcXxRinuPDPyL9eime9HxK_epzn4u766vbyU3nz5ePny4ubkoxRa4k9E3cBZad7Q9I0CtCS0pK49rZuyHCwLXlZd6FpiBpFWlojlVe99kGrc_H21HtY5h8bp9WNMREPg5943pJDi3WrDBibrfpkpWVOaeHeHZY4-uXeIbgjKbd3J1LuSMpBFkKOvXncsHUjh7-hP2iy4cPJwPnOfPviEkWeiENmQasLc_zfhn8LaMggyQ_f-Z7Tft6WKTN06JJ04L4ev3V8FhoA1KDVA43wj4w</recordid><startdate>20151001</startdate><enddate>20151001</enddate><creator>Muradian, Kh</creator><creator>Vaiserman, A</creator><creator>Min, K.-J</creator><creator>Fraifeld, V.E</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20151001</creationdate><title>Fucoxanthin and lipid metabolism: A minireview</title><author>Muradian, Kh ; Vaiserman, A ; Min, K.-J ; Fraifeld, V.E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c553t-1fecebd12b4f5c2583017c342ce6a768c5ed79ca26bd88cc83c427523a3f4ad43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adipocyte differentiation</topic><topic>Adipocytes - cytology</topic><topic>Adiponectin</topic><topic>Animals</topic><topic>Anti-Obesity Agents</topic><topic>Brown seaweeds</topic><topic>Cardiovascular</topic><topic>Cell Differentiation - drug effects</topic><topic>Diet, High-Fat</topic><topic>Fucoxanthin</topic><topic>Humans</topic><topic>Ion Channels</topic><topic>Leptin</topic><topic>Lipid Metabolism - drug effects</topic><topic>Lipids - blood</topic><topic>Lipogenesis - drug effects</topic><topic>Lipolysis - drug effects</topic><topic>Liver - drug effects</topic><topic>Liver - metabolism</topic><topic>Lypogenesis and lipolysis</topic><topic>Mice</topic><topic>Mitochondrial Proteins</topic><topic>Obesity</topic><topic>Rats</topic><topic>Rodents</topic><topic>Uncoupling Protein 1</topic><topic>Uncoupling proteins</topic><topic>Weight Gain - drug effects</topic><topic>Xanthophylls - administration & dosage</topic><topic>Xanthophylls - therapeutic use</topic><topic>Xanthophylls - toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Muradian, Kh</creatorcontrib><creatorcontrib>Vaiserman, A</creatorcontrib><creatorcontrib>Min, K.-J</creatorcontrib><creatorcontrib>Fraifeld, V.E</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Nutrition, metabolism, and cardiovascular diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Muradian, Kh</au><au>Vaiserman, A</au><au>Min, K.-J</au><au>Fraifeld, V.E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fucoxanthin and lipid metabolism: A minireview</atitle><jtitle>Nutrition, metabolism, and cardiovascular diseases</jtitle><addtitle>Nutr Metab Cardiovasc Dis</addtitle><date>2015-10-01</date><risdate>2015</risdate><volume>25</volume><issue>10</issue><spage>891</spage><epage>897</epage><pages>891-897</pages><issn>0939-4753</issn><eissn>1590-3729</eissn><abstract>Abstract Aims Accumulating data suggest that food supplementation with seaweeds which traditionally are an important part of food culture in South-East Asian countries might lead to essential health benefits. In this short review, we summarize findings from experimental studies on the effects of fucoxanthin (a carotenoid derived from brown seaweeds) on lipid metabolism, adiposity, and related conditions and discuss the possible underlying mechanisms. Data synthesis Supplementation of fucoxanthin or its derivatives consistently attenuated body and visceral fat weight gain, lipid accumulation in the liver, decreases insulin resistance, and improves the plasma lipid profile in rodents fed a high-fat diet. It should however be noted that in diabetic/obese KK-Ay mice with genetically compromised insulin signaling, fucoxanthin might increase the plasma levels of cholesterol and low-density lipoproteins. The anti-obesity effects of fucoxanthin are apparently mediated by the hormones leptin and adiponectin through their common target AMK-activated protein kinase, resulting in downregulation of lipogenic enzymes and upregulation of lipolytic enzymes. Fucoxanthin also suppresses adipocyte differentiation and induces the expression of uncoupling proteins in visceral adipose tissue. Conclusions The results of experimental studies suggest that consumption of fucoxanthin and its derivatives as nutritional supplements is a promising option for prevention and treatment of obesity and a wide variety of related pathologies, including metabolic syndrome, type 2 diabetes, and heart disease. Yet, clinical trials are warranted to assess a therapeutic value of fucoxanthin.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>26141943</pmid><doi>10.1016/j.numecd.2015.05.010</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0939-4753 |
ispartof | Nutrition, metabolism, and cardiovascular diseases, 2015-10, Vol.25 (10), p.891-897 |
issn | 0939-4753 1590-3729 |
language | eng |
recordid | cdi_proquest_miscellaneous_1716935057 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete |
subjects | Adipocyte differentiation Adipocytes - cytology Adiponectin Animals Anti-Obesity Agents Brown seaweeds Cardiovascular Cell Differentiation - drug effects Diet, High-Fat Fucoxanthin Humans Ion Channels Leptin Lipid Metabolism - drug effects Lipids - blood Lipogenesis - drug effects Lipolysis - drug effects Liver - drug effects Liver - metabolism Lypogenesis and lipolysis Mice Mitochondrial Proteins Obesity Rats Rodents Uncoupling Protein 1 Uncoupling proteins Weight Gain - drug effects Xanthophylls - administration & dosage Xanthophylls - therapeutic use Xanthophylls - toxicity |
title | Fucoxanthin and lipid metabolism: A minireview |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-11T15%3A21%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fucoxanthin%20and%20lipid%20metabolism:%20A%20minireview&rft.jtitle=Nutrition,%20metabolism,%20and%20cardiovascular%20diseases&rft.au=Muradian,%20Kh&rft.date=2015-10-01&rft.volume=25&rft.issue=10&rft.spage=891&rft.epage=897&rft.pages=891-897&rft.issn=0939-4753&rft.eissn=1590-3729&rft_id=info:doi/10.1016/j.numecd.2015.05.010&rft_dat=%3Cproquest_cross%3E1716935057%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1716935057&rft_id=info:pmid/26141943&rft_els_id=1_s2_0_S0939475315001404&rfr_iscdi=true |